Floatz logo

FILGRASTIM

Hepatoblastoma

Xinhua Hospital, Shanghai Jiao Tong University School of Medicineprotein_peptidePhase 4 / ApprovedDormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

29 Active assets in the Hepatoblastoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Children's Oncology Group
Phase 3BB
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 2BB
(+)-VINCRISTINE
University of Birmingham
Phase 3BB
Eloxatin
Children's Oncology Group
Phase 3BB
Irinotecan
Children's Oncology Group
Phase 3BB

View all 46 →

Same molecule, other indications

FILGRASTIM is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
79 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →